Botswana Pharmaceuticals and Healthcare Report Q4 2017
Botswana's pharmaceutical sector is expected to achieve bullish growth rates over our forecast period, more than doubling its small market size. The government will remain committed to improving healthcare infrastructure in the country and to tackling the nation's high communicable disease burden, particularly HIV/AIDS. However, the country's small market size will dampen multinational interest, with drugmakers choosing South Africa as a regional hub.
Headline Expenditure Projections
Pharmaceuticals: BWP2.05bn (USD188mn) in 2016 to BWP2.23bn (USD211mn) in 2017; +9.0% in local currency terms and +12.2% in US dollar terms.
Healthcare: BWP9.00bn (USD827mn) in 2016 to BWP9.78bn (USD925mn) in 2017; +8.6% in local currency terms and +11.9% in US dollar terms.
Risk/Rewards Index Sub-Saharan Africa is a region with high variability of market attractiveness for innovative drugmakers. While certain markets hold significant opportunities for the commercialisation of pharmaceuticals, the region itself lags behind global standards in all areas given its underdeveloped nature. As such, it is vital that companies appreciate the varying levels of investment risks and rewards that are present in the markets in Sub-Saharan Africa. BMI's Innovative Pharmaceuticals Risk/Reward Index tool, which provides a globally comparative and numerically based assessment of a market's attractiveness for companies looking to launch a high-value drug, was established to address this.